SOMERSET, New Jersey, March 23, 2022–(BUSINESS WIRE)–Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company that develops, manufactures and markets novel therapies to treat life-threatening diseases, was recognized at the 10th annual Biotech Trophy Foreign Investment, organized by Flanders Investment & Trade (FIT) was named Newcomer of the Year.
Flanders Investment and Trade is a Flemish government organization that facilitates investment projects in Flanders, a region in northern Belgium, and supports Flemish companies. The Foreign Investment Trophy recognizes international companies with investment projects in Flanders, and the FIT Newcomer of the Year award is given to companies that have recently started major investment projects in the region.
Legend Biotech received the award for its joint investment with Janssen Pharmaceutica NV (Janssen) in a state-of-the-art manufacturing facility in Flanders. The facility is the first cell therapy manufacturing plant in Flanders and is intended to serve as a regional hub for the company’s cell therapy manufacturing for patients in Europe, the Middle East and Africa.
The 26,000-square-foot manufacturing facility is part of Legend’s collaboration with Janssen to advance the manufacturing of Ciltacabtagene Autoleucel (Cilta-Cel). This is a CAR-T treatment based on B-cell maturation antigens that is currently under review by the European Medicines Agency for the treatment of relapsed or refractory multiple myeloma. In April 2019, Cilta-Cel received PRIME status (Priority Medicines). PRIME status enables increased interaction and early dialogue with developers of promising drug candidates to optimize drug development plans and accelerate the evaluation of innovative scientific advances targeting large unmet medical needs.
The European manufacturing center is expected to be operational in 2023 and will be run by Legend Biotech.
Accepting the award in Belgium, Ying Huang, PhD, CEO and CFO of Legend Biotech said, “This award is a special recognition of our investments in Flanders, one of the most exciting biotech hubs in Europe. The Newcomer of the Year award reflects how far we have come since Legend’s inception in applying cell therapies to rare and unusual diseases. We look forward to advancing this goal and playing an important role in the Ghent ecosystem.”
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating life-threatening diseases with the goal of one day curing them. Headquartered in Somerset, New Jersey, the company develops advanced cell therapies across multiple technology platforms, including autologous and allogeneic chimeric antigen receptor T-cells, T-cell receptors (TCR-T), and natural killer cell-based immunotherapies ( NK). At our three research and development sites around the world, we apply these innovative technologies to develop safe, effective and cutting-edge therapies for patients around the world.
For more information visit www.legendbiotech.com and follow us Twitter as well as on LinkedIn.
About Flanders Investment & Trade
Flanders Investment & Trade (FIT) actively promotes sustainable international business in Flanders as a key element of the region’s socio-economic development. To achieve this, FIT supports Flemish-based companies in their international projects and attracts foreign investors. FIT helps companies throughout Flanders with their international activities and offers personalized advice and support. Companies can take advantage of the agency’s local and international network, and FIT also offers financial support and information on available financial incentives.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding future expectations, plans and prospects, and all other statements about matters that are not historical facts, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to statements about Legend Biotech’s strategies and objectives, statements about CARVYKTI™, including Legend Biotech’s expectations for CARVYKTI™, such as Legend Biotech’s expectations for the manufacture and commercialization of CARVYKTI™ and the potential effect of CARVYKTI™ treatment, statements regarding the filing and progress of Cilta-Cel applications with the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) , the China Center for Drug Evaluation, the National Medical Products Administration (CDE) and other regulatory agencies; timeline and ability to advance clinical trials, including patient recruitment; submit investigational new drug (IND) applications to regulatory authorities and maintain such applications with regulatory authorities; the ability to generate, analyze, and present clinical trial data; and the potential benefits of Legend Biotech’s product candidates. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “potential”, “predict”, “project”, “should”, “intends”, “will”, “could” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results could differ materially from those projected in such forward-looking statements due to a number of important factors. Factors that could affect Legend Biotech’s expectations include: uncertainties in the development of new pharmaceutical products; unexpected clinical trial results, including additional analyzes of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or data analysis or regulatory requirements generally; unexpected delays resulting from the actions or omissions of our partners; uncertainties arising from challenges to Legend Biotech’s patents or other intellectual property, including uncertainties associated with US litigation; competition in general; pricing and other political restrictions by government, industry, and the public; the duration and severity of the COVID-19 pandemic and the government measures taken in response to the evolving situation; and the other factors described in the “Risk Factors” section of Legend Biotech’s annual report filed with the Securities and Exchange Commission on April 2, 2021. If one or more of these risks or uncertainties materialize, or if assumptions underlying statements prove incorrect, actual results may differ materially from those described, anticipated, believed, estimated or anticipated in this press release. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech expressly disclaims any obligation to undertake to update any forward-looking statement, whether as a result of new information, future events or otherwise.
The source language in which the original text is published is the official and authorized version. Translations will be included for better understanding. Only the version in the language that was originally published is legally valid. Therefore, compare the translations with the original language version of the publication.
View the original version on businesswire.com: https://www.businesswire.com/news/home/20220323005186/en/
Tina Carter, Corporate Communications Lead, Legend Biotech
Joanne Choi, Senior Investor Relations Manager, Legend Biotech
Crystal Chen, Investor Relations Manager, Legend Biotech